John Wityak

4.5k total citations
46 papers, 1.4k citations indexed

About

John Wityak is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, John Wityak has authored 46 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Cellular and Molecular Neuroscience and 10 papers in Organic Chemistry. Recurrent topics in John Wityak's work include Genetic Neurodegenerative Diseases (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Platelet Disorders and Treatments (7 papers). John Wityak is often cited by papers focused on Genetic Neurodegenerative Diseases (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (8 papers) and Platelet Disorders and Treatments (7 papers). John Wityak collaborates with scholars based in United States, Germany and Japan. John Wityak's co-authors include Shaker A. Mousa, Joel C. Barrish, James C. Lin, Celia Dominguez, Arthur M. Doweyko, Ruth R. Wexler, Jagabandhu Das, Robert V. Moquin, Ding Ren Shen and Gary L. Schieven and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

In The Last Decade

John Wityak

46 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Wityak United States 24 581 554 179 171 143 46 1.4k
John H. Hutchinson United States 26 654 1.1× 882 1.6× 147 0.8× 57 0.3× 214 1.5× 90 1.9k
Shin‐ichi Tsukamoto Japan 22 652 1.1× 765 1.4× 147 0.8× 89 0.5× 119 0.8× 71 1.6k
Peter D. Davis United Kingdom 19 554 1.0× 1.2k 2.2× 299 1.7× 75 0.4× 177 1.2× 39 2.0k
Thomas Weller Switzerland 23 502 0.9× 514 0.9× 91 0.5× 210 1.2× 75 0.5× 48 2.2k
Daniel E. Levy United States 14 292 0.5× 516 0.9× 122 0.7× 55 0.3× 70 0.5× 32 1.0k
Laurie Churchill United States 13 260 0.4× 686 1.2× 263 1.5× 79 0.5× 146 1.0× 20 1.3k
Patrick A. Plé United Kingdom 17 572 1.0× 877 1.6× 445 2.5× 124 0.7× 83 0.6× 30 1.5k
Thais M. Sielecki United States 18 420 0.7× 378 0.7× 280 1.6× 73 0.4× 104 0.7× 26 1.1k
Thomas W. Ku United States 19 315 0.5× 469 0.8× 197 1.1× 54 0.3× 150 1.0× 33 1.1k
Loredana Vesci Italy 30 558 1.0× 1.1k 2.1× 563 3.1× 79 0.5× 61 0.4× 73 2.0k

Countries citing papers authored by John Wityak

Since Specialization
Citations

This map shows the geographic impact of John Wityak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Wityak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Wityak more than expected).

Fields of papers citing papers by John Wityak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Wityak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Wityak. The network helps show where John Wityak may publish in the future.

Co-authorship network of co-authors of John Wityak

This figure shows the co-authorship network connecting the top 25 collaborators of John Wityak. A scholar is included among the top collaborators of John Wityak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Wityak. John Wityak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huhtala, Tuulia, Pekka Poutiainen, Jussi Rytkönen, et al.. (2019). Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors. EJNMMI Radiopharmacy and Chemistry. 4(1). 20–20. 9 indexed citations
2.
Bresciani, Alberto, Roberto Boggio, Cristina Cariulo, et al.. (2018). Quantifying autophagy using novel LC3B and p62 TR-FRET assays. PLoS ONE. 13(3). e0194423–e0194423. 34 indexed citations
3.
Verhaeghe, Jeroen, Daniele Bertoglio, David Thomae, et al.. (2018). Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt. Frontiers in Neurology. 9. 516–516. 21 indexed citations
4.
Bertoglio, Daniele, Jeroen Verhaeghe, David Thomae, et al.. (2018). Longitudinal Characterization of mGluR5 Using 11C-ABP688 PET Imaging in the Q175 Mouse Model of Huntington Disease. Journal of Nuclear Medicine. 59(11). 1722–1727. 12 indexed citations
5.
Bertoglio, Daniele, Jeroen Verhaeghe, David Thomae, et al.. (2018). MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington’s disease. PLoS ONE. 13(10). e0206613–e0206613. 19 indexed citations
6.
Häggkvist, Jenny, Miklós Tóth, Katarina Varnäs, et al.. (2016). Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. Journal of Nuclear Medicine. 58(4). 617–622. 14 indexed citations
7.
Todd, Daniel G., Simon DOWLER, Michael D. Wall, et al.. (2014). A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease. PLoS ONE. 9(2). e87923–e87923. 70 indexed citations
8.
Epple, Robert, et al.. (2006). 新規PPARδ作動薬としての3,4,5‐三置換イソオキサゾール:1部. Bioorganic & Medicinal Chemistry Letters. 16(16). 4376–4380. 17 indexed citations
9.
Epple, Robert, Mihai Azimioara, Yongping Xie, et al.. (2006). 3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2. Bioorganic & Medicinal Chemistry Letters. 16(21). 5488–5492. 26 indexed citations
10.
Das, Jagabandhu, Chunjian Liu, Robert V. Moquin, et al.. (2006). Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(14). 3706–3712. 64 indexed citations
11.
Purandare, Ashok V., Honghe Wan, John E. Somerville, et al.. (2005). Identification of chemokine receptor CCR4 antagonist. Bioorganic & Medicinal Chemistry Letters. 15(10). 2669–2672. 54 indexed citations
12.
Wityak, John, Jagabandhu Das, Robert V. Moquin, et al.. (2003). Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck. Bioorganic & Medicinal Chemistry Letters. 13(22). 4007–4010. 39 indexed citations
13.
Chen, Ping, Derek Norris, Edwin J. Iwanowicz, et al.. (2002). Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56Lck. Bioorganic & Medicinal Chemistry Letters. 12(10). 1361–1364. 28 indexed citations
14.
Chen, Ping, Edwin J. Iwanowicz, Derek Norris, et al.. (2002). Synthesis and SAR of novel imidazoquinoxaline-Based Lck inhibitors: improvement of cell potency. Bioorganic & Medicinal Chemistry Letters. 12(21). 3153–3156. 13 indexed citations
15.
Sielecki, Thais M., John Wityak, Shaker A. Mousa, et al.. (2000). Ring constrained analogues of β-alanine-containing GPIIb/IIIa receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 10(5). 449–452. 6 indexed citations
16.
Wityak, John, et al.. (1999). Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate. Bioorganic & Medicinal Chemistry Letters. 9(2). 123–126. 5 indexed citations
17.
Mousa, Shaker A., et al.. (1998). XV454, a Novel Nonpeptide Small-Molecule Platelet GIIb/IIIa Antagonist with Comparable Platelet αIIbβ3-Binding Kinetics to c7E3. Journal of Cardiovascular Pharmacology. 32(5). 736–744. 13 indexed citations
18.
Mousa, Shaker A., Richard E. Olson, Jeffrey M. Bozarth, et al.. (1998). Oral Antiplatelet Efficacy and Specificity of a Novel Nonpeptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802. Journal of Cardiovascular Pharmacology. 32(2). 169–176. 13 indexed citations
19.
Mousa, Shaker A., Mark S. Forsythe, William Lorelli, et al.. (1996). Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754. Coronary Artery Disease. 7(10). 767–774. 41 indexed citations
20.
Gould, Steven J., et al.. (1991). Biosynthesis of streptothricin F. Bioorganic Chemistry. 19(3). 333–350. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John H. Hutchinson Breakdown of academic impact, for papers by Shin‐ichi Tsukamoto Breakdown of academic impact, for papers by Peter D. Davis Breakdown of academic impact, for papers by Thomas Weller Breakdown of academic impact, for papers by Daniel E. Levy Breakdown of academic impact, for papers by Laurie Churchill Breakdown of academic impact, for papers by Patrick A. Plé Breakdown of academic impact, for papers by Thais M. Sielecki Breakdown of academic impact, for papers by Thomas W. Ku Breakdown of academic impact, for papers by Loredana Vesci
Rankless by CCL
2026